What is the recommended administration schedule for lurbinectedin?

Standard Dosing Schedule

Lurbinectedin (brand name Zepzelca) is administered intravenously at 3.2 mg/m² over 60 minutes on day 1 of a 21-day cycle. Patients receive this until disease progression or unacceptable toxicity.[1]

Premedication Requirements

Give dexamethasone 10 mg IV 30 minutes before each infusion, plus antiemetics like ondansetron and aprepitant to prevent nausea and vomiting.[1]

Dosage Adjustments for Toxicity

Reduce to 2.6 mg/m² (80% of starting dose) or 2.0 mg/m² (60%) for severe hematologic or non-hematologic toxicities. Withhold for grade 3/4 neutropenia, thrombocytopenia, or other grade 3/4 events until recovery to grade 1 or baseline.[1]

How Long Do Patients Stay on Treatment?

Continue cycles until progression, with median duration around 4-5 months in trials for relapsed small cell lung cancer. No fixed limit if tolerated.[1][2]

Who Approves This Schedule?

FDA approved in June 2020 for metastatic small cell lung cancer after platinum-based therapy, based on PMB trial data showing 35% overall response rate.[1][3]

Special Considerations for Liver or Kidney Issues

No adjustment for mild liver impairment (bilirubin ≤1.5x ULN); avoid in moderate/severe cases. Use caution with CrCl 30-89 mL/min; not studied below 30 mL/min.[1]

[1]: Zepzelca Prescribing Information (FDA)
[2]: PMB Trial Results (NEJM)
[3]: FDA Approval Summary